Open-Labeled Trial Of Direct-Acting Antiviral Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors
Latest Information Update: 19 Jun 2023
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms THINKER
- 01 Mar 2023 Status changed from active, no longer recruiting to completed.
- 04 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.
- 13 Jul 2021 Status changed from recruiting to active, no longer recruiting.